BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower multiple applied to the firm’s 2025 EPS forecast due to weaker earnings visibility and compression in the group average P/E multiple from tariffs and also drug pricing concerns. Ahead of the company’s Q1 report, the firm updated its U.S. Eylea estimates for the impact from the patient assistance funds closing, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Downgraded to Sell Amid Eylea Sales Decline and Market Pressures
- Regeneron’s odronextamab granted FDA orphan designation
- Resilient Outlook: Regeneron’s Strong Financial Projections Amid Foundation Closure Challenges
- Regeneron price target lowered to $940 from $950 at Guggenheim
- Regeneron price target lowered to $1,081 from $1,150 at Morgan Stanley